Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
Preliminary results from the FULCRUM-VT trial point to a safer, more effective way to treat ventricular tachycardia—a dangerous heart rhythm disorder that can lead to sudden cardiac arrest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback